HiFiBiO Therapeutics is an innovative multinational company dedicated to harnessing the power of the human immune system to combat cancer and autoimmune diseases. As a clinical-stage global biotech headquartered in Cambridge, MA, HiFiBiO is at the forefront of developing high-resolution translational solutions to enhance the success of therapies. The company's vision is to pioneer curative immunotherapies for every patient, while their mission is to unlock the curative abilities of the immune system through innovative biotherapeutics, ultimately improving patient lives.

HiFiBiO achieves this through their unique single-cell driven Drug Intelligence Science (DIS®) platform, which combines advanced single-cell capabilities with artificial intelligence and machine learning to discover novel targets, effective antibody drugs, and predictive biomarkers. Led by a team of experienced leaders, including Founder, Chairperson, and CEO Dr. Liang Schweizer, Chief Scientific Officer Dr.

Francisco Adrian, and Chief Medical Officer Dr. Robert Andtbacka, HiFiBiO's expertise spans research, industry, and clinical development. With a dedication to advancing a sustainable pipeline of breakthrough immunotherapies, HiFiBiO Therapeutics is revolutionizing the field and driving transformative change in the fight against cancer and autoimmune diseases